22 Jul AffyImmune Therapeutics
Daniel Janse, Ph.D., CEO
Oct. 8 | 2:15pm | FLW Ballroom G
Natick, MA
(Private)
AffyImmune is a clinical-stage biopharmaceutical company committed to developing a first-in-class, ICAM-1 targeting and affinity-tuned LFA-1 binder CAR T therapy to transform the lives of patients with advanced solid cancers. The Company’s proprietary technology utilizing ICAM-1/LFA-1 interaction can potentially address the critical CAR T challenges such as toxicity, antigen loss, T-cell trafficking and exhaustion, while also allowing in vivo tracking of the CAR T cells. Its lead candidate, AIC100, is currently in a Phase 1 study to treat patients with advanced thyroid cancers including advanced differentiated thyroid cancer (ADTC) and anaplastic thyroid cancer (ATC). AffyImmune is developing a focused pipeline in ICAM-1-positive cancers with high unmet medical need.
